Key Highlights
- 0.66 is the net loss per share Aardvark Therapeutics (NASDAQ:AARD) reported for the second quarter of 2026, unchanged from a year earlier, on a net loss of USD 14.4 million.
- 73.9 is the cash, cash equivalents and short-term investments balance in USD million at June 30, 2026, down from USD 91.2 million at March 31, 2026, with runway guided into late 2027.
- 10.5 is the second quarter 2026 Research and Development expense in USD million, down from USD 13.1 million a year earlier after the trial pause and FDA clinical hold in May 2026.
- 4.6 is the second quarter 2026 general and administrative expense in USD million, up from USD 2.7 million, including USD 0.5 million of severance linked to a June 2026 workforce reduction.
What Investors Expect From Aardvark Therapeutics (NASDAQ:AARD) on November 16, 2026
Aardvark Therapeutics is scheduled to report third quarter 2026 results on November 16, 2026. The benchmark is the second quarter, when the net loss was USD 14.4 million, or 0.66 per share, matching the prior-year quarter. Total operating expenses were USD 15.1 million versus USD 15.8 million, while other income, net, fell to USD 0.7 million from USD 1.5 million. For the first half the net loss was USD 36.0 million, or 1.65 per share, against USD 23.7 million, or 1.36 per share, a year earlier. The company is a clinical-stage developer and does not report product revenue.
The Rationale: Last Reported Quarter and Management Outlook for Aardvark Therapeutics (NASDAQ:AARD)
The quarter was shaped by regulatory events involving ARD-101, the company's lead candidate for Prader-Willi syndrome. In May 2026 the FDA placed a full clinical hold on the ARD-101 IND following a voluntary pause, and in June 2026 the company terminated the HERO Phase 3 trial and its open-label extension, stating that it does not currently intend to resume them as previously designed. Management said it was assessing unblinded HERO and extension data in the third quarter of 2026 to inform next steps and remained in active discussions with the FDA on the hold. A workforce reduction followed in June 2026. The release gave no readout date for HERO.
Valuation, Liquidity and Risks for Aardvark Therapeutics (NASDAQ:AARD)
Aardvark Therapeutics ended June 30, 2026 with USD 73.9 million of cash and short-term investments, a decline of USD 17.3 million (calculated) from March 31, 2026. Management says the balance funds projected operations into late 2027. Total Assets were USD 81.5 million, total liabilities were USD 6.7 million and stockholders' Equity was USD 74.8 million. Shares outstanding were 21,884,158 at June 30, 2026, compared with 21,815,353 at December 31, 2025. Principal risks include the regulatory path for ARD-101, the outcome of the data review, further cost reductions and the need for future financing beyond the guided runway.
Where Things Stand
Aardvark Therapeutics (NASDAQ:AARD) reports on November 16, 2026 after a quarter marked by a full FDA clinical hold in May 2026, termination of the HERO and extension trials in June 2026 and a workforce reduction. The second quarter net loss of USD 14.4 million, or 0.66 per share, was flat on a per-share basis year over year. Research spending fell to USD 10.5 million while administrative costs rose to USD 4.6 million. With USD 73.9 million of cash and short-term investments and runway guided into late 2027, the update on unblinded data and FDA discussions is the central item.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...